Judge rules: Orphan drugs not subject to 340B discounts
October 16th 2015Judge Rudolph Contreras ruled against the Department of Health and Human Services by saying that pharma companies do not have to offer rural and cancer hospitals that serve low-income populations 340B discounts on orphan drugs.
Read More
MS drugs make major advancements
October 9th 2015There is new hope for patients with multiple sclerosis (MS) after positive data on Gilenya and the investigational drug ocrelizumab was presented at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain.
Read More
FDA expands use for lung cancer drug
October 9th 2015Soon after the FDA granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC), it approved Opdivo (nivolumab) for an expanded use – to treat patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy.
Read More
Be ready to track ACO industry in wake of CMS ACO 2014 quality report
October 9th 2015On the heels of the Centers for Medicare & Medicaid Services release of the Medicare accountable care organizations (ACO) 2014 quality and financial performance results, tracking the ACO industry for market shifts might be a wise move, according to one industry expert.
Read More
Three tips: Prepare for new rewards program reporting
October 6th 2015CMS recently released a proposed draft of its Medicare Reporting Requirements document for 2016 and, for the first time, the guidance includes reporting requirements for Medicare rewards and incentive programs. The new reporting requirement is slated to begin January 1. Are you ready?
Read More